Exhibit 99.1
Juniper Pharmaceuticals Reports Second Quarter 2018
Financial and Operating Results
Signs Agreement to be Acquired by Catalent, Inc.
CRINONE® Revenues Increased 12% and Juniper Pharma Services (JPS)
Revenues Increased 41% for the Six-months Ended June 30, 2018 vs. Prior Year
BOSTON, August 9, 2018 — Juniper Pharmaceuticals, Inc. (Nasdaq:JNP), a diversified healthcare company with core businesses of its CRINONE® (progesterone gel) franchise and fee-for-service pharmaceutical development and manufacturing business, Juniper Pharma Services (“JPS”), today announced financial results for the quarterly period ended June 30, 2018. Cash and equivalents were $20.8 million at June 30, 2018 compared to $20.7 million at March 31, 2018.
“Last month, we achieved the key objective in our efforts to maximize shareholder value, announcing a definitive agreement with Catalent, Inc. for the acquisition of all outstanding shares of Juniper at terms which reflect the value of our businesses,” said Alicia Secor, Chief Executive Officer. “We would like to thank our shareholders for their continued support.”
Second Quarter and Recent Corporate Highlights
| • | Signed a definitive agreement for Catalent, Inc. (“Catalent”) to acquire all outstanding shares of Juniper Pharmaceuticals, Inc. (“Juniper” or “Juniper Pharmaceuticals”). The transaction, approved unanimously by the Juniper Board of Directors, represents a total equity value of approximately $139.6 million on a fully-diluted basis. Under the terms of the definitive agreement, Catalent has commenced a tender offer to acquire all of the outstanding shares of Juniper’s common stock at a price of $11.50 per share. The closing of the tender offer will be subject to a majority of Juniper’s outstanding shares being tendered in the tender offer. In addition, the transaction is subject to other customary closing conditions. Following completion of the tender offer, Catalent will acquire all remaining shares at the same price of $11.50 per share |
| through a second step merger, other than shares that have properly effected appraisal rights. The closing of the transaction is expected to take place in the third quarter of 2018. |
| • | Signed an exclusive, worldwide license agreement with Daré Bioscience, Inc. (“Daré”) for the development and commercialization of Juniper’s intravaginal ring (“IVR”) technology platform, including its three preclinical IVR candidates targeting unmet needs in women’s health. Under the agreement, Daré will be responsible for conducting all research, development and commercial activities for this program. |
Second Quarter 2018 Financial Results
Second quarter 2018 total revenues increased 10% to $15.3 million, compared with $14.0 million for the quarter ended June 30, 2017.
Product revenues were $9.3 million compared to $9.6 million in the second quarter of 2017.
Service revenues from JPS were $5.7 million, an increase of $1.3 million, versus $4.4 million in the second quarter of last year, driven by new and existing customer growth.
Gross profit was $6.2 million as compared to $6.3 million in the prior year quarter.
Total operating expenses were $8.1 million in the second quarter of 2018, compared to $6.7 million in the prior year quarter. The increase is largely attributed to transaction-related costs.
Juniper recorded net loss of $1.5 million in the second quarter of 2018, or $0.14 net loss per diluted share, compared to a net loss of $0.4 million, or $0.03 net loss per diluted share, in the same period of 2017.
Liquidity
Cash and cash equivalents were $20.8 million as of June 30, 2018 versus $20.7 million at March 31, 2018.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc.‘s core businesses include its CRINONE® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. Please visit www.juniperpharma.com for more information.
Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.
CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan plc in the U.S.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the expected timetable for completing the Catalent transaction, the tender offer process, including the timing of and the satisfaction or waiver of closing conditions to the acquisition. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainty associated with being able to identify, evaluate and complete any strategic alternative, the impact of the announcement of Juniper’s review of strategic alternatives, as well as any strategic alternative that may be pursued, on Juniper’s business, including its financial and operating results and its employees and customers, risks associated with the drug development process generally, including the outcomes of clinical trials and the regulatory review process; the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies or following commercial launch, if such product candidates are approved; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with Juniper Pharmaceuticals’ ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from currently approved therapies and from other companies developing products for similar uses; risk associated with Juniper Pharmaceuticals’ ability to manage operating expenses and/or obtain additional funding to support its business activities; and risks associated with
Juniper Pharmaceuticals’ dependence on third parties, including dependence on its partner to develop and commercialize Juniper’s IVR technology platform and related preclinical IVR candidates. For a discussion of certain risks and uncertainties associated with Juniper Pharmaceuticals’ forward-looking statements, please review Juniper’s reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2017, its Quarterly Report on Form 10-Q for the periods ended March 31, 2018 and June 30, 2018 and subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management’s current expectations and Juniper Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.
Additional Information and Where to Find It
This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substitute for the tender offer materials that Catalent and Catalent Boston, Inc., a wholly owned subsidiary of Catalent (“Merger Sub”), filed with the SEC on July 17, 2018. Catalent and Merger Sub filed a tender offer statement on Schedule TO with the SEC, and Juniper filed a solicitation/recommendation statement on Schedule 14D-9 with respect to the tender offer. THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY AND CONSIDERED BY THE JUNIPER’S STOCKHOLDERS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Both the tender offer statement and the solicitation/recommendation statement were mailed to the Juniper’s stockholders free of charge. A free copy of the tender offer statement and the solicitation/recommendation statement is also available to all of Juniper’s stockholders by accessing Juniper Pharmaceuticals, Inc.’s website at http://ir.juniperpharma.com/sec-filings or upon written request to Juniper Pharmaceuticals, Inc., 33 Arch Street, Boston, MA 02110. In addition, the tender offer statement and the solicitation/recommendation statement (and all other documents filed with the SEC) are available at no charge on the SEC’s website at www.sec.gov.
JUNIPER’S STOCKHOLDERS ARE ADVISED TO READ THE SCHEDULE TO AND THE SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO.
Investor Contact:
Argot Partners
Laura Perry or Heather Savelle
212-600-1902
laura@argotpartners.com
heather@argotpartners.com
To receive Juniper’s press releases, SEC filings or calendar alerts by email click here.
Follow us on LinkedIn
JUNIPER PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands)
| June 30, 2018 |
December 31, 2017 |
|||||||
| Assets |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 20,826 | $ | 21,446 | ||||
| Accounts receivable, net |
10,772 | 4,734 | ||||||
| Inventories |
6,280 | 6,326 | ||||||
| Prepaid expenses and other current assets |
3,228 | 3,467 | ||||||
|
|
|
|
|
|||||
| Total current assets |
41,106 | 35,973 | ||||||
| Property and equipment, net |
17,074 | 15,229 | ||||||
| Intangible assets, net |
587 | 744 | ||||||
| Goodwill |
8,928 | 9,123 | ||||||
| Other assets |
73 | 151 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 67,768 | $ | 61,220 | ||||
|
|
|
|
|
|||||
| Liabilities and stockholders’ equity |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 7,173 | $ | 4,038 | ||||
| Accrued expenses and other |
7,398 | 5,615 | ||||||
| Deferred revenue |
887 | 6,141 | ||||||
| Current portion of long-term debt |
544 | 546 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
16,002 | 16,340 | ||||||
| Long-term debt, net of current portion |
2,909 | 3,253 | ||||||
| Deferred tax liability |
300 | — | ||||||
| Other non-current liabilities |
64 | 115 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
19,275 | 19,708 | ||||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
48,493 | 41,512 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 67,768 | $ | 61,220 | ||||
|
|
|
|
|
|||||
JUNIPER PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share data)
| Three Months Ended June 30 |
Six Months Ended June 30 |
|||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||
| Revenues |
||||||||||||||||
| Product revenues |
$ | 9,343 | $ | 9,569 | $ | 19,417 | $ | 17,295 | ||||||||
| Service revenues |
5,717 | 4,387 | 11,167 | 7,908 | ||||||||||||
| License revenues |
250 | — | 250 | — | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total revenues |
15,310 | 13,956 | 30,834 | 25,203 | ||||||||||||
| Cost of product revenues |
6,158 | 5,303 | 12,174 | 9,617 | ||||||||||||
| Cost of service revenues |
2,959 | 2,347 | 5,969 | 4,590 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total cost of revenues |
9,117 | 7,650 | 18,143 | 14,207 | ||||||||||||
| Gross profit |
6,193 | 6,306 | 12,691 | 10,996 | ||||||||||||
| Operating expenses |
||||||||||||||||
| Sales and marketing |
563 | 410 | 982 | 788 | ||||||||||||
| Research and development |
1,055 | 1,648 | 2,029 | 2,994 | ||||||||||||
| General and administrative |
6,518 | 4,604 | 10,607 | 9,025 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
8,136 | 6,662 | 13,618 | 12,807 | ||||||||||||
| Income (loss) from operations |
(1,943 | ) | (356 | ) | (927 | ) | (1,811 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Interest expense, net |
(29 | ) | (30 | ) | (74 | ) | (58 | ) | ||||||||
| Other income, net |
758 | 10 | 559 | 52 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total non-operating income |
729 | (20 | ) | 485 | (6 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Income (loss) before income taxes |
(1,214 | ) | (376 | ) | (442 | ) | (1,817 | ) | ||||||||
| Income tax (benefit) expense |
300 | — | 300 | — | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income (loss) |
$ | (1,514 | ) | $ | (376 | ) | $ | (742 | ) | $ | (1,817 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Basic net income (loss) per common share |
$ | (0.14 | ) | $ | 0.01 | $ | (0.07 | ) | $ | (0.13 | ) | |||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted net income (loss) per common share |
$ | (0.14 | ) | $ | (0.03 | ) | $ | (0.07 | ) | $ | (0.13 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Basic weighted average common shares outstanding |
11,103 | 10,803 | 11,023 | 10,803 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted weighted average common shares outstanding |
11,103 | 10,954 | 11,023 | 10,803 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||